We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.47%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.02B
AUM Growth
+$399M
Cap. Flow
+$261M
Cap. Flow %
8.64%
Top 10 Hldgs %
52.67%
Holding
175
New
36
Increased
34
Reduced
22
Closed
43

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$50.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$40.2M
3
MMSI icon
Merit Medical Systems
MMSI
+$32.5M
4
ABMD
Abiomed Inc
ABMD
+$30.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.5M
2
NXTM
NxStage Medical Inc.
NXTM
+$34.9M
3
TSRO
TESARO, Inc.
TSRO
+$25.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Discretionary 0.06%
3 Technology 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKBA icon
26
Akebia Therapeutics
AKBA
$338M
$29.6M 0.98%
1,987,400
+357,400
+22% +$5.93M
XNCR icon
27
Xencor
XNCR
$1.45B
$28.8M 0.95%
1,313,095
+20,000
+2% +$434K
ISRG icon
28
Intuitive Surgical
ISRG
$127B
$25.8M 0.85%
211,755
-15,000
-7% -$1.88M
CBAY
29
DELISTED
Cymabay Therapeutics
CBAY
$24.7M 0.82%
2,685,882
+335,000
+14% +$2.86M
BOLD
30
DELISTED
Audentes Therapeutics, Inc
BOLD
$24.4M 0.81%
781,309
– –
ASMB icon
31
Assembly Biosciences
ASMB
$498M
$24.3M 0.8%
44,719
+7,900
+21% +$3.58M
ZBH icon
32
Zimmer Biomet
ZBH
$18.8B
$24.1M 0.8%
+206,000
New +$23.3M
DBVT
33
DBV Technologies
DBVT
$813M
$24.1M 0.8%
97,862
+40,220
+70% +$11.6M
IRTC icon
34
iRhythm Holdings
IRTC
$4.02B
$24M 0.79%
427,371
+54,700
+15% +$2.86M
WVE icon
35
Wave Life Sciences
WVE
$1.12B
$23.3M 0.77%
662,798
+20,000
+3% +$583K
RYTM icon
36
Rhythm Pharmaceuticals
RYTM
$7.31B
$21.7M 0.72%
+745,135
New +$19.7M
ALDX icon
37
Aldeyra Therapeutics
ALDX
$97.1M
$21M 0.7%
3,085,458
– –
VRTX icon
38
Vertex Pharmaceuticals
VRTX
$123B
$20.8M 0.69%
138,626
– –
QURE icon
39
uniQure
QURE
$2.75B
$20.5M 0.68%
1,047,950
+7,831
+0.8% +$119K
NEPT
40
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$19.8M 0.66%
5,981
+1,324
+28% +$2.4M
AVDL
41
DELISTED
Avadel Pharmaceuticals
AVDL
$19.6M 0.65%
2,391,841
+842,836
+54% +$7.9M
LKFT
42
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$19.3M 0.64%
206,305
-100
-0% -$9.46K
HUM icon
43
Humana
HUM
$43.9B
$19.2M 0.64%
77,500
-22,500
-23% -$5.56M
KDMN
44
DELISTED
Kadmon Holdings, Inc.
KDMN
$18.8M 0.62%
5,185,847
– –
SRRA
45
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$18.6M 0.62%
125,000
+33,620
+37% +$3.23M
NVTA
46
DELISTED
Invitae Corporation
NVTA
$18.2M 0.6%
2,004,500
+120,000
+6% +$1.08M
MDGL icon
47
Madrigal Pharmaceuticals
MDGL
$12.6B
$17.3M 0.57%
+188,893
New +$10.8M
ABEOW
48
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$14.6M 0.48%
1,259,636
– –
RVNC
49
DELISTED
Revance Therapeutics, Inc.
RVNC
$14.3M 0.47%
+400,000
New +$11.5M
ADMA icon
50
ADMA Biologics
ADMA
$2.02B
$12.3M 0.41%
3,821,102
+3,100,000
+430% +$8.67M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Perceptive Advisors held 175 positions worth $3.02B, up 15% from $2.62B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $261M of net new capital in Q4 2017, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Zimmer Biomet: 206,000 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $57.5M trimmed.

  • Perceptive Advisors's largest Q4 2017 buy was Zimmer Biomet: 206,000 shares worth $24.1M.
  • Perceptive Advisors added most to Blueprint Medicines in Q4 2017, an estimated $50.4M increase.
  • Perceptive Advisors's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $57.5M.
  • Perceptive Advisors fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $34.9M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.02B portfolio in Q4 2017.
  • Perceptive Advisors opened 36 new positions and closed 43 in Q4 2017.
  • Perceptive Advisors's portfolio value rose 15% quarter-over-quarter to $3.02B.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.